201 related articles for article (PubMed ID: 12618529)
1. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation.
Faccio R; Takeshita S; Zallone A; Ross FP; Teitelbaum SL
J Clin Invest; 2003 Mar; 111(5):749-58. PubMed ID: 12618529
[TBL] [Abstract][Full Text] [Related]
2. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation.
Kim HH; Chung WJ; Lee SW; Chung PJ; You JW; Kwon HJ; Tanaka S; Lee ZH
Exp Cell Res; 2003 Oct; 289(2):368-77. PubMed ID: 14499638
[TBL] [Abstract][Full Text] [Related]
5. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
[TBL] [Abstract][Full Text] [Related]
6. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
7. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
[TBL] [Abstract][Full Text] [Related]
8. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand.
Miyamoto T; Arai F; Ohneda O; Takagi K; Anderson DM; Suda T
Blood; 2000 Dec; 96(13):4335-43. PubMed ID: 11110710
[TBL] [Abstract][Full Text] [Related]
9. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
10. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology.
Ross FP; Teitelbaum SL
Immunol Rev; 2005 Dec; 208():88-105. PubMed ID: 16313343
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
13. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
16. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
17. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
18. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.
Arai F; Miyamoto T; Ohneda O; Inada T; Sudo T; Brasel K; Miyata T; Anderson DM; Suda T
J Exp Med; 1999 Dec; 190(12):1741-54. PubMed ID: 10601350
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
20. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
